Загрузка...
Germlining of the HIV-1 broadly neutralizing antibody domain m36
Engineered antibody domains (eAds) have emerged as a novel class of HIV-1 inhibitors and are currently under preclinical testing as promising drug candidates for prevention and therapy of HIV-1 infection. Reverse mutation of antibodies to germline sequences (germlining) could not only identify less...
Сохранить в:
| Опубликовано в: : | Antiviral Res |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4357557/ https://ncbi.nlm.nih.gov/pubmed/25676867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2015.02.001 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|